AgingResearch.NewsJoin free

Dimerix

CompanyAustralia

Dimerix develops one asset, in phase 2 (MTX652 in acute kidney injury). Mostly small molecule acting on autophagy and USP30; based in Australia.

1
Asset
Furthest stage
Phase 2
0
Trials
0
Signals

Pipeline

1

  • MTX652

    Inhibits USP30 to promote mitophagy.

    Phase 2, Small molecule, Autophagy, USP30, acute kidney injury, heart Failure/HFpEF

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Similar companies6

Intelligence